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Abstract
Background: Chromosome 15q14-22.1 has been linked to type 2 diabetes (T2D) and its related traits in Japanese and
other populations. The presence of T2D disease susceptibility variant(s) was assessed in the 21.8 Mb region between
D15S118 and D15S117 in a Japanese population using a region-wide case-control association test.
Methods: A two-stage association test was performed using Japanese subjects: The discovery panel (Stage 1) used 372
cases and 360 controls, while an independent replication panel (Stage 2) used 532 cases and 530 controls. A total of 1,317
evenly-spaced, common SNP markers with minor allele frequencies > 0.10 were typed for each stage. Captured genetic
variation was examined in HapMap JPT SNPs, and a haplotype-based association test was performed.
Results: SNP2140 (rs2412747) (C/T) in intron 33 of the ubiquitin protein ligase E3 component n-recognin 1 (UBR1) gene
was selected as a landmark SNP based on repeated significant associations in Stage 1 and Stage 2. However, the marginal
p value (p = 0.0043 in the allelic test, OR = 1.26, 95% CI = 1.07–1.48 for combined samples) was weak in a single locus
or haplotype-based association test. We failed to find any significant SNPs after correcting for multiple testing.
Conclusion: The two-stage association test did not reveal a strong association between T2D and any common variants
on chromosome 15q14-22.1 in 1,794 Japanese subjects. A further association test with a larger sample size and denser
SNP markers is required to confirm these observations.
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Background
Insulin resistance in muscle, adipose, and liver tissues and
impaired insulin secretion from pancreatic β cells contrib-
ute to the pathogenesis of type 2 diabetes (T2D) [1]. Anal-
yses using a traditional candidate gene approach and,
more recently, genome-wide association studies (GWAS)
[2-7], have generated a large amount of data that have
confirmed 11 genes with replicated association with T2D
in Caucasians [8]. However, the assessment in Japanese
T2D patients, who characteristically have a lower body
mass index (BMI) and a lower fasting insulin level than
Caucasians [9], has not been largely performed. These dif-
ferences suggest that Japanese individuals with T2D might
have a different genetic background from other popula-
tions, and susceptibility variant(s) or gene(s) for the
development of T2D in Japanese can only be identified
with genetic assessment. Because candidate regions sup-
ported by replicated linkage signals in Japanese and other
populations are expected to map T2D susceptibility
gene(s), a region-wide association test was used as an
alternative affective approach with the availability of
unbiased reliability, timeliness and cost efficiency.
Among a number of proposed candidate regions for T2D
and its related traits [10], the chromosome 15q14-22.1
candidate region is supported by replicated linkage signals
of non-overlapping samples from Japanese subjects. In
three studies of genome-wide linkage scan of Japanese
subjects [11-13], chromosome 15q14-22.1 showed signif-
icant evidence of linkage with T2D (LOD = 2.41) [12] and
a maximum LOD score (MLS) of 3.91 for early onset T2D
[11] (Table 1). This region overlaps candidate region
found in other populations, including Mexican Americans
[14] and Pima Indians [15], findings that were replicated
in a subsequent study of Mexican Americans [16] (Table
1). This candidate region supported by replicated linkage
signals is expected to contain susceptibility gene(s). In the
absence of convincing comprehensive association data on
chromosome 15q, the challenge remains to identify the
disease susceptibility variant(s) or gene(s) that defini-
tively contribute to T2D. We focused on chromosome
15q14-22.1 at 32.6–51.2 cM as the susceptibility region in
Japanese.
In this study, a region-wide two-stage association test was
used to perform a comprehensive examination of genetic
variant(s), using 1,317 common SNPs, in a Japanese pop-
ulation comprised of 1,794 unrelated cases and controls.
Methods
Subjects
This study utilized samples obtained from a total of 1,794
Japanese subjects: 904 T2D cases and 890 controls. The
majority of T2D patients was recruited from the outpa-
tient clinic of Tokushima University Hospital, Kyoto Pre-
fectural University Hospital and their affiliated hospitals.
All T2D diagnoses were based on the 1985 World Health
Organization criteria, and patients were clinically defined
as having gradual adult onset of the disease with medica-
tion. Patients with clinical criteria for monogenic forms of
diabetes were excluded. The clinical characteristics of
these samples are presented in Table 2. The controls were
recruited from healthy adult members of the general pop-
ulation, who were intensively checked for a negative fam-
ily history of diabetes, normal HbA1c levels of < 5.8%, the
absence of other diseases, and Japanese ancestry based on
Table 1: Summary of linkage scan on chromosome 15q14-22.1
Population Sample Score Phenotype STS marker Position (cM) References (year)
Japanese 224 ASP in 159 families, 359 
individuals
1.57 MLS T2D D15S994 40.25 Mori Y et al. 2002 [11]
3.91 MLS T2D (Young-onset < 45) D15S994 40.25
2.44 MLS T2D (BMI < 30) D15S994 40.25
1.50 MLS T2D D15S118 32.58
0.95 MLS T2D D15S117 51.21
Japanese 256 ASP in 164 families, 368 
individuals
2.41 LOD T2D (BMI < 22) CYP19 45.62 Iwasaki N et al. 2003 [12]
Japanese 102 ASP in 102 families 0.25 LOD T2D D15S117 51.21 Nawata H et al. 2004 [13]
Mexican Americans 330 ASP in 170 families, 408 
individuals
1.50 MLS T2D D15S119 45.62 Hanis CL et al. 1996 [14]
Pima Indians 388 ASP in 109 families, 363 
individuals
1.46 LOD insulin secretion (IVGTT 
10)
D15S659 43.47 Pratley RE et al. 1998 [15]
Mexican Americans 330 ASP in 170 families and 
363 nondiabetic individuals
1.27 LOD T2D D15S119 45.62 Cox NJ et al. 1999 [16]
interaction with D15S119 
and CYP19
4.00 LOD T2D D15S119+ CYP19
ASP, affected sib-pairs; MLS, maximum lod score; LOD, logarithm of odds; IVGTT 10, plasma insulin response at 10 min above the basal level during 
the intravenous glucose tolerance test; D15S119 + CYP19, D15S119 interaction with CYP19 (NIDDM1). Each report identified nominal evidence 
of linkage or significant evidence of linkage with LOD > 3.91. Location is shown only for loci with positive evidence of linkage on chromosome 15q. 
The position is based on the Marshfield recombination genetic map .
http://research.marshfieldclinic.org/genetics/Home/index.aspBMC Medical Genetics 2008, 9:22 http://www.biomedcentral.com/1471-2350/9/22
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their birthplace information. The controls were primarily
recruited from the Pharma SNP Consortium (nation-wide
collection of Japanese control subjects) [17] and obtained
through the Health Science Research Resources Bank of
the Japanese Collection of Research/Japan Health Science
Foundation. The subjects were placed in one of two inde-
pendent panels: the discovery panel (Stage 1; 372 cases
and 360 controls) and the replication panel (Stage 2; 532
cases and 530 controls).
Genomic DNA was prepared from peripheral blood leu-
kocytes or EB-virus-immortalized B lymphoblasts using a
standard protocol. The study was approved by the Ethical
Committee for Human Genome and Gene Research at the
University of Tokushima in accordance with the tenets of
the Declaration of Helsinki. Informed consent was
obtained from all subjects prior to blood sampling, and
all personal information and samples were anonymously
analyzed for genotyping.
Association testing of SNP markers and genotyping
At the onset of this study, there was no sufficient SNPs
database, such as HapMap. Thus, we constructed a data-
base of common Japanese SNPs based on the genotyping
results of 45 unrelated Japanese control subjects (23
males and 22 females) in a whole genome in collabora-
Table 2: Characteristics of the 1,794 Japanese subjects used in the association tests
Stage 1 samples (discovery panel) Cases (n = 372) Controls (n = 360)
Gender (M/F) 188/184 148/212
Age 64.4 ± 10.3 46.3 ± 19.9
HbA1C (%) 7.39 ± 1.48 4.79 ± 0.36
BMI (kg/m2) 23.7 ± 3.5 22.0 ± 2.9
Age at onset < 50 (%) 175 (47.0) -
≥50(%) 195 (52.5) -
unknown (%) 2 (0.5) -
Family history (%) 125 (33.6) -
Diabetes in both parents 11
Diabetes in one parent 110
Diabetes in son or daughter 4
Insulin therapy (+) (%) 112 (30.1) -
Stage 2 samples (replication panel) Cases (n = 532) Controls (n = 530)
Gender (M/F) 246/286 284/246
Age 62.0 ± 10.7 37.8 ± 11.3
HbA1C (%) 7.47 ± 1.43 4.88 ± 0.33
BMI (kg/m2) 23.6 ± 3.3 22.4 ± 3.0
Age at onset < 50 (%) 244 (45.9) -
≥50(%) 287 (53.9) -
unknown (%) 1 (0.2) -
Family history (%) 207 (38.9) -
Diabetes in both parents 22
Diabetes in one parent 180
Diabetes in son or daughter 5
Insulin therapy (+) (%) 172 (32.3) -
Stage 1 + Stage 2 combined samples Cases (n = 904) Controls (n = 890)
Gender (M/F) 434/470 432/458
Age 63.0 ± 10.6 41.2 ± 15.9
HbA1C (%) 7.43 ± 1.45 4.84 ± 0.34
BMI (kg/m2) 23.6 ± 3.4 22.3 ± 3.0
Age at onset < 50 (%) 419 (46.4) -
≥50(%) 482 (53.3) -
unknown (%) 3 (0.3) -
Family history (%) 332 (36.7) -
Diabetes in both parents 33
Diabetes in one parent 290
Diabetes in son or daughter 9
Insulin therapy (+) (%) 284 (31.4) -BMC Medical Genetics 2008, 9:22 http://www.biomedcentral.com/1471-2350/9/22
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tion with Applied Biosystems (ABI) [18]. Out of 70,099
common (MAF > 0.15) gene-centric and intergenic SNPs
made available by this project, we provisionally selected
1,450 evenly-spaced SNPs on chromosome 15q between
two sequence-tagged site (STS) markers of D15S118 and
D15S117.
The initial selection was based on the following criteria: 1)
optimal suitability for the design of TaqMan high-
throughput genotyping assays; 2) dense and evenly-
spaced SNP coverage in both coding and intergenic
regions; 3) definition of the gene location in a region
between 10 kb upstream of the transcription start site and
10 kb downstream of the final exon; 4) a distance < 10 kb
between adjacent SNPs; and 5) common SNPs with a MAF
> 0.10. The criterion of a MAF > 0.10 was imposed subse-
quent to the selection of SNPs with a MAF > 0.15.
SNPs were assayed using TaqMan Universal PCR Master-
Mix (no UNG; ABI) as previously described [19-21]. The
genotyping results were obtained in an auto-call mode,
after which two researchers independently assessed the
genotyping data. When the ratio of undetermined results
to the total samples was greater than 2% (8/384 including
four negative controls) or negative controls without DNA
template were incorrectly detected, the genotyping was
repeated. Genotyping results were compared to those
obtained by direct sequencing as previously described
[20] with perfect agreement between the two methods.
Two-stage design of the association test
We performed a two-stage association test on 1,794 sam-
ples by randomly assigning them to two independent
panels. In the first test, all of the SNPs were genotyped in
Stage 1. Those exhibiting significant allelic or genotypic
association (p < 0.05) were further examined in Stage 2. In
each stage, the association was evaluated with two types of
χ2 test (allelic or genotypic) by 2 × 2 and 2 × 3 contingency
tables for the status of cases or controls. Finally, the asso-
ciation was evaluated using the combined samples from
both Stages.
The power of this case-control test was calculated based
on MAF, a type 1 error rate (false-positive rate), and sam-
ple size with the PS program [22,23]. The standard Bon-
ferroni's correction was used to evaluate the false-positive
rate [24]. In addition, we used the false discovery rate
(FDR) approach [25] as implemented with the FDR con-
trol program in the R language [26]. A logistic regression
analysis to adjust for age, gender, and BMI was carried out
using the SPSS program (ver.12, SPSS Japan Inc., Tokyo,
Japan).
Searching for novel SNPs and mutational screening of the 
UBR1 gene
The 47 coding exons, relevant intron-exon boundaries,
and 5' and 3' UTR of UBR1 gene were screened for puta-
tive novel Japanese variants by direct sequencing the
genomic DNA of 48 individuals (24 cases and 24 con-
trols). All PCR products were treated with ExoSAP-IT (GE
Healthcare, NJ, USA) and sequenced using BigDye Termi-
nator Cycle Sequencing Kit, ver1.1 (ABI) in both direc-
tions on a 3730xl automated sequencer (ABI) according to
the manufacturer's standard protocol.
Estimation of linkage disequilibrium (LD) analysis for 
haplotype inference
Pairwise LD coefficients of |D'| and r2 were assessed in
Stage 1 samples with SNPAlyze ver 5.1 Pro software
(DYNACOM, Japan) [27]. This analysis was performed
under the assumption of Hardy-Weinberg equilibrium.
Haplotype frequencies for multiple loci were estimated by
the maximum-likelihood method with an expectation-
maximization (EM) algorithm. Permutation p values were
calculated by comparing haplotype frequencies between
cases and controls on the basis of 10,000 replications.
Haplotype-tagging SNPs (htSNPs) were determined with
SNPAlyze ver 5.1 Pro.
The amount of captured genetic variation based on 
HapMap JPT SNPs
HapMap JPT SNPs corresponding to 21.8 Mb were inves-
tigated [28]. Information on 29,728 SNPs within the tar-
get region was downloaded from the HapMap website
(release 22) [29]. The density of the 1,317 SNPs (the
finally selected SNPs from the 1,450 pre-HapMap SNPs)
per 300-kb bin was compared against those in the Hap-
Map JPT SNPs. In addition, we estimated the captured tag
SNPs as proxies at r2 > 0.7, 0.8, or 0.9 using Tagger pro-
gram [30].
Results
Information of selected SNPs
One STS marker (D15S118) was located 3.9 Mb proximal
to  D15S994, which exhibited the highest evidence for
linkage in the Japanese subjects with a LOD = 3.91. The
second STS marker (D15S117) located 9.0 Mb distal to
D15S119, was linked to T2D susceptibility in Mexican
Americans with a LOD = 4.0 (Table 1). Therefore, a 21.8
Mb interval between D15S118 (32.6 cM, mp; 34.5 Mb)
and D15S117 (51.2 cM, mp; 56.3 Mb) was chosen as the
target region.
Out of 1,450 SNPs, quality control resulted in the exclu-
sion of 39 SNPs that exhibited ambiguous genotyping
qualities. After genotyping the remaining 1,411 SNPs,
another 94 with a HWE p < 0.05 or a low MAF of < 0.10,
an indication of insufficient power to detect statistical sig-BMC Medical Genetics 2008, 9:22 http://www.biomedcentral.com/1471-2350/9/22
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nificance, were excluded. In the final selection of 1,317
SNPs, 974 were mapped within 152 genes (65.8% of the
231 genes based on the NCBI Build 36.1 [31] human
genome assembly), and 343 were located in intergenic
regions. The average MAF of the 1,317 SNPs was 0.32 ±
0.11 in Stage 1 samples, and the average spacing of the
gene-centric SNPs was 9,169 bp per pair of SNPs across
the 21.8 Mb.
Captured genetic variation relative to HapMap JPT SNPs 
in the target region
Coverage of the 1,317 SNPs was more limited than that
with 29,728 SNPs of HapMap JPT in the 21.8 Mb region:
1,022 SNPs (78%) of the 1,317 SNPs were present, while
only 295 SNPs (22%) were not present in the 29,728 Hap-
Map JPT (Figure 1), although they were registered in the
public database [32] without information on allele fre-
quency in the Japanese population. Figure 1 shows only
one gap in 43.6–43.9 Mb in this study, and the presence
of a rare density of SNPs (< 10) was observed, particularly
in the intergenic region and between 42.1–44.8 Mb.
This approach is more efficient if tag SNPs based on the
HapMap JPT r2 structure are used to find the susceptibility
variant [28]. We estimated the captured tag SNPs as prox-
ies, meaning that the SNP showed a strong correlation
with one or more SNPs at r2 > 0.7, 0.8, or 0.9. The density
of most tag SNPs was < 10 SNPs per 300-kb bin (Figure 1).
Taken together, the coverage of common SNPs variation
by our chosen SNP set was rather balanced in both gene-
centric and intergenic regions, and the average number of
common tag SNPs in this study was 30% of those in the
HapMap JPT (r2 > 0.8).
SNP marker distribution in the target region Figure 1
SNP marker distribution in the target region. Distribution of 1,317 SNPs selected for this study (1), 1,022 identical (2), 
and 295 non-identical (3) SNPs in the HapMap JPT database, and distribution of 29,728 SNPs in HapMap JPT (10) in every 300-
kb bin against the physical distance in the target region. Number of tag SNPs (r2 > 0.7, 0.8, and 0.9) found for this study 
matched with the r2 > 0.7, 0.8, and 0.9 SNPs in HapMap JPT (4, 5, and 6) and number of tag SNPs (r2 > 0.7, 0.8, and 0.9) among 
the HapMap JPT SNPs (7, 8, and 9). The vertical bars in the top panel show the position of RefSeq genes in this region.
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Selection of a landmark SNP
In Stage 1 association test, 112 SNPs out of 1,317 (8.5%)
showed significant associations (χ2 test, p < 0.05) in the
allelic (Figure 2A) or genotypic test. In Stage 2, 11 SNPs
out of 112 yielded significant associations (p < 0.05) in
the allelic (Figure 2B) or genotypic test. However, only
one SNP, namely SNP2140 (rs2412747), showed a repli-
cated association for the allelic test (p < 0.05) in both
stages (Figure 2C). These results suggest that our associa-
tion test is underpowered. None of the other SNPs
showed replicated association for genotypic frequency
(Additional file 1).
When the raw data from Stage 1 and Stage 2 were com-
bined, SNP2140 in intron 33 of the ubiquitin protein
ligase E3 component n-recognin 1 (UBR1) gene exhibited
the nominal significant association with T2D in both the
allelic (p = 0.0043, OR = 1.26, 95% CI = 1.07–1.48) (Fig-
ure 2C) and genotypic (p = 0.0081) tests. However, a
logistic regression analysis revealed that the association
between SNP2140 and T2D was not statistically signifi-
cant after adjustment for age, gender, and BMI. In addi-
tion, when the standard Bonferroni's correction for
multiple testing was applied (corrected for 1,317 SNPs in
the allelic and genotypic tests), the association with
SNP2140 was no longer significant. Moreover, FDR for
Association tests on chromosome 15q14-22.1 Figure 2
Association tests on chromosome 15q14-22.1. Allelic p values in association tests are shown. The top window shows 
reports of linkage with T2D or its related traits on chromosome 15q14-22.1 in the Japanese and other ethnic populations. The 
solid and open circles denote LOD scores and location in recombination distance. The width of the straight lines or a broken 
line denote a 1-LOD drop interval when available. The vertical bars show the positions of RefSeq genes (upper) and the 1,317 
chosen SNPs (lower) with black vertical bars placed in gene-centric regions and gray vertical bars in intergenic regions. Allelic 
p values in Stage 1 (372 cases and 360 controls) for 1,317 SNPs (A), in Stage 2 (532 cases and 530 controls) for 112 SNPs (B), 
and in Stage 1 + Stage 2 combined samples (904 cases and 890 controls) for one replicated SNP (C) were plotted against phys-
ical positions. The data denote the -log p, and p = 0.05 is shown with a thick line. The landmark SNP2140 (rs2412747) is indi-
cated with an arrow.
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112 SNPs in the Stage 2 association test was not signifi-
cant at a threshold value of 0.1 [25].
The results of association for the top 20 Stage 1-associa-
tions using the Armitage trend test are shown in Table 3.
Based on the combined p values, three SNPs (SNP3347:
rs1386166, SNP3096: rs156787, and SNP2072:
rs936216) showed a smaller p value than the landmark
SNP2140 in the allelic test (Table 3). However, none of
the three SNPs showed significant association in Stage 2,
although sample size and power to detect susceptibility
SNPs was larger than in Stage 1. We believe that the SNP
with replicated significance in both Stage 1 and Stage 2 is
regarded as the more likely SNP for T2D association.
Unfortunately, none of 112 SNPs reached the statistical
confidence level in our sample population.
We next searched for novel SNPs or mutation in the UBR1
gene. Two novel non-synonymous SNPs (M1359I in exon
37 and R1712H in exon 47) were identified by re-
sequencing the UBR1 gene in 48 samples. The SNPs were
not common (MAF = 0.02 and 0.01) and subsequent typ-
ing of all of the samples revealed no significance for these
two variants in the allelic test (p = 0.17 and 0.96 for com-
bined samples). To confirm our data, it will be necessary
to test association using a larger number of independent
samples.
Fine LD mapping and a haplotype-based association test
Haplotype-based association tests assessed as a multi-
locus test can be more sensitive for the detection of asso-
ciation than assessment by a single-locus association test.
To perform this test, we examined LD structure with the
pairwise |D'| values of the region, including the UBR1
gene. We searched for additional common variants
around putative LD block boundaries with available data-
base. Using the definition of |D'| > 0.95, we identified a
large LD block consisting of 38 SNPs including seven
additional SNPs spanning 355 kb across the UBR1 gene.
None of the seven SNPs showed a significant association
in Stage 1, Stage 2, or in the combined samples.
For fine mapping of the 355 kb LD block, we selected
seven haplotype-tagging SNPs (htSNPs) from 38 SNPs
that captured > 95% of haplotype frequencies comprising
the respective block in all samples, and estimated a haplo-
type-based association test. A protective haplotype and at-
risk haplotype showed a nominal permutation p value
(0.005 and 0.03 for combined samples) with T2D (Addi-
tional file 2). However, after Bonferroni's correction (cor-
rected for 1,317 SNPs multiplied by two + eight
haplotypes), p values were not significant for either haplo-
type.
Discussion
We applied a region-wide association test as an alternative
to GWAS. This approach has been effective in the identifi-
cation of candidate susceptibility genes in the target
regions for T2D [19,20] and rheumatoid arthritis [33,34]
in the Japanese population. We hypothesized that there
was a high probability of detecting disease susceptibility
genes with the use of evenly-spaced common SNP mark-
ers in the target region defined by replicated linkage evi-
dence. We could not find any strong variant with single-
locus association test or haplotype analysis in 1,794 Japa-
nese subjects, although one SNP, SNP2140 (rs2412747),
in intron 33 of the UBR1 gene showed nominal signifi-
cance (p = 0.0043 for combined samples).
UBR1 encodes an E3 ubiquitin ligase of the N-end rule
pathway, a conserved proteolytic pathway of the ubiqui-
tin system whose substrates include proteins with destabi-
lizing N-terminal residues. Recent data suggest that in
Johanson-Blizzard syndrome (OMIM 243800), the pan-
creas exhibits pancreatic exocrine insufficiency and does
not express UBR1  [35].  Ubr1  knockout mice exhibit
decreased body weight or adipose tissue and an exocrine
pancreatic insufficiency [35,36]. In addition, UBR1
mRNA is elevated in the atrophic muscles of diabetic rats
[37]. At present, however, the pathophysiological mecha-
nism by which the UBR1 influences T2D is unknown.
Genetic association tests aim to detect true positive asso-
ciations between a trait and genetic polymorphisms while
eliminating false positives. The results of this study have
been evaluated within the framework of several criteria.
Accordingly, the statistical power (with a MAF of 0.30) in
Stage 1 or Stage 2 showed 22–60% or 29–76%, respec-
tively, at detecting the OR of 1.2–1.4 at a significance level
of 0.05 (Figure 3A, B). Although the power using the
whole sample size was estimated as 45–93%, it was not
sufficient to detect an association with T2D (Figure 3C).
To achieve 60–80% power (with a MAF of 0.30 and OR of
1.2), 1,400–2,200 each for case and control samples
(almost twice as many as those in each stage of this study)
is needed. Recent GWAS analyzed more than one thou-
sand cases and controls in Stage 1 and up to more than
10,000 samples in total [2-7], as recommended [38]. Rep-
lication studies with thousands of subjects are a priority to
determine the consistency of our observations of the
UBR1  gene, because it is predicted that true variant(s)
have only a modest effect on T2D.
Our samples had the major weakness of an age difference
between the case and control subjects (63.0 vs. 41.2).
After logistic regression analysis, the association with
SNP2140 did not remain statistically significant after
adjustment for age and gender. Because aging is an impor-
tant factor in diabetes development, it is necessary to con-B
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Table 3: Top 20 SNPs and the landmark SNP2140 in Stage 1 allelic and genotypic association tests
Stage 1 Stage 2 Stage 1 + Stage 2
SNP 
Marker
rs# Gene 
symbol
Position Allele 1/2 Allele 1 
frequency 
case
Allele 1 
frequency 
control
p value of 
allele 
frequency
p value of 
genotype 
frequency
p value of 
Armitage 
trend testa)
Allele 1 
frequency 
case
Allele 1 
frequency 
control
p value of 
allele 
frequency
p value of 
genotype 
frequency
p value of 
Armitage 
trend testa)
Allele 1 
frequency 
case
Allele 1 
frequency 
control
p value of 
allele 
frequency
p value of 
genotype 
frequency
p value of 
Armitage 
trend testa)
1 SNP2248 - ATP8B4 4817563
2
G/T 0.23 0.31 0.00053 0.0024 0.00052 0.29 0.28 0.59 0.61 0.59 0.27 0.30 0.075 0.19 0.075
2 SNP2372 rs426146
8
RAB27A 5334289
4
A/G 0.49 0.41 0.00091 0.0034 0.00078 0.47 0.48 0.67 0.80 0.66 0.48 0.45 0.076 0.20 0.072
3 SNP3295 rs124431
71
intergenic 4822510
7
C/T 0.34 0.43 0.00091 0.0030 0.00099 0.38 0.40 0.49 0.66 0.49 0.37 0.41 0.0079 0.018 0.0081
4 SNP3347 rs138616
6
intergenic 5137677
2
A/G 0.35 0.44 0.0014 0.0013 0.0016 0.37 0.40 0.15 0.23 0.16 0.36 0.42 0.0017 0.0080 0.0021
5 SNP1439 rs997247
8
RAB27A 5334702
4
A/C 0.30 0.23 0.0017 0.0068 0.0016 0.27 0.29 0.28 0.34 0.27 0.28 0.26 0.25 0.37 0.25
6 SNP3391 rs241435
1
intergenic 5274656
5
C/G 0.24 0.18 0.0019 0.0066 0.0017 0.19 0.21 0.16 0.39 0.17 0.21 0.20 0.34 0.64 0.35
7 SNP2373 rs230542
4
RAB27A 5336864
0
C/T 0.47 0.55 0.0037 0.011 0.0032 0.48 0.48 0.97 0.86 0.96 0.48 0.51 0.061 0.11 0.058
8 SNP1441 rs241440
9
PIGB 5341900
9
C/T 0.47 0.55 0.0039 0.013 0.0034 0.48 0.48 0.93 0.91 0.93 0.48 0.51 0.077 0.16 0.074
9 SNP1280 rs227816
7
SLC27A2 4828514
0
G/T 0.61 0.54 0.0050 0.014 0.0047 0.59 0.56 0.20 0.095 0.19 0.60 0.55 0.0054 0.013 0.0047
10 SNP2039 rs241242
4
FSIP1 3776542
5
C/T 0.65 0.59 0.0075 0.022 0.0061 0.62 0.62 0.91 0.62 0.91 0.64 0.61 0.072 0.16 0.067
11 SNP2098 rs492452
4
CHAC1 3904267
3
C/T 0.76 0.70 0.0060 0.022 0.0064 0.73 0.76 0.21 0.082 0.21 0.75 0.73 0.42 0.15 0.42
12 SNP1440 rs718396
0
PIGB 5340998
7
C/T 0.47 0.54 0.0074 0.022 0.0067 0.48 0.48 0.80 0.93 0.79 0.48 0.50 0.13 0.26 0.13
13 SNP2249 rs116388
41
ATP8B4 4820389
9
C/G 0.73 0.66 0.0062 0.026 0.0069 0.67 0.68 0.72 0.89 0.72 0.70 0.67 0.15 0.33 0.15
14 SNP3176 rs996215 intergenic 4457711
4
A/G 0.23 0.30 0.0067 0.027 0.0073 0.28 0.27 0.51 0.74 0.50 0.26 0.28 0.22 0.46 0.22
15 SNP2097 rs492452
3
CHAC1 3904266
2
A/T 0.24 0.30 0.0072 0.025 0.0076 0.27 0.24 0.22 0.085 0.22 0.26 0.27 0.43 0.15 0.43
16 SNP2072 rs936216 PAK6 3834456
0
A/C 0.75 0.81 0.0092 0.0075 0.0084 0.75 0.78 0.093 0.14 0.10 0.75 0.79 0.0032 0.015 0.0038
17 SNP1438 rs129109
30
RAB27A 5333299
8
C/G 0.33 0.27 0.0095 0.016 0.0084 0.28 0.31 0.20 0.25 0.20 0.30 0.29 0.49 0.24 0.49
18 SNP2041 rs225482
9
FSIP1 3777995
7
C/T 0.66 0.59 0.0099 0.030 0.0085 0.63 0.62 0.84 0.67 0.84 0.64 0.61 0.071 0.17 0.068
19 SNP1444 rs374320
3
CCPG1 5343625
4
C/T 0.47 0.53 0.010 0.037 0.010 0.47 0.47 0.98 0.83 0.98 0.47 0.49 0.11 0.22 0.10
20 SNP3096 rs156787 FLJ39531 3733561
9
A/G 0.18 0.23 0.0092 0.038 0.011 0.18 0.21 0.065 0.065 0.062 0.18 0.22 0.0020 0.0041 0.0022
* SNP214
0
rs24127
47
UBR1 4107409
5
C/T 0.81 0.77 0.049 0.11 0.049 0.79 0.75 0.039 0.072 0.039 0.80 0.76 0.0043 0.0081 0.0045
Significant results (p < 0.05) and (*) SNP2140 (rs2412747) in the UBR1 are shown in bold type. a)Armitage trend test was performed by using the DeFinetti program http://ijg.gsf.de/cgi-bin/hw/hwal.pl. The 
positions of top 20 SNPs with their p values in the increasing order in Armitage trend test are almost the same as those in allelic test, except for SNP 2039, 1440, and 3096 of which p values were underlined.BMC Medical Genetics 2008, 9:22 http://www.biomedcentral.com/1471-2350/9/22
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firm the result of our association test using age-matched
control subjects. In selecting the target region for associa-
tion assessment, the initial linkage studies might overesti-
mate the relevance of chromosome 15q as a candidate
region in the Japanese population. The linkage of chro-
mosome 15q14-22.1 to T2D and its related traits have
been replicated in the Japanese at a significant level (LOD
= 3.91). However, this LOD score was observed in cases
with young onset (< 45 years of age) T2D, which is not
reflected in our cases (average age = 63.0).
Though SNPs markers were placed, on average, every
9,169 bp, which is comparable in density to a genome-
wide association test using a 500 kb SNP set (~6 kb), it
might be necessary to use denser SNPs with shorter inter-
vals. Even though tag SNPs were not available at the onset
of this study, tag SNPs with LD information and a high-
density SNP map from the HapMap data would afford
useful resources.
Based on these results, we propose that the discovery of a
landmark SNP, SNP2140, in the UBR1 gene was statisti-
cally marginal and did not reach the confidence level of
this study. Other SNPs did not exhibit a strong effect on
the risk of T2D within the target region, despite suggestive
replicated evidence for linkage in the Japanese popula-
tion. In addition, a replication study is of prime impor-
tance for confirmation of these results.
Conclusion
The two-stage association test on chromosome 15q14-
22.1 failed to detect an association between T2D and
SNPs in the target region. These observations could
uncover new insights on the susceptibility variant(s) on
chromosome 15q that might be used as a guide for further
association tests, including replication and/or meta-anal-
ysis. Replication studies in other independent popula-
tions are a priority if the consistency of our observations
is to be determined.
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Power calculation Figure 3
Power calculation. The power of this case-control associa-
tion test to detect association against the risk allele fre-
quency with a type 1 error rate of 0.05 in Stage 1 samples 
(A), in Stage 2 samples (B), and combined samples (C). 372 
cases and 360 controls subjects were set in Stage 1, 532 
cases and 530 controls subjects were set in Stage 2, and 904 
and 890 controls subjects were set in Stage 1 + Stage 2 com-
bined samples with variable power and a type 1 error rate of 
0.05. A) – C) graphs were plotted with the PS program.
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